These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 12477383)

  • 21. A review of the clinical efficacy and safety of 5alpha-reductase inhibitors for the enlarged prostate.
    Naslund MJ; Miner M
    Clin Ther; 2007 Jan; 29(1):17-25. PubMed ID: 17379044
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of finasteride is maintained in patients with benign prostatic hyperplasia treated for 5 years. The North American Finasteride Study Group.
    Hudson PB; Boake R; Trachtenberg J; Romas NA; Rosenblatt S; Narayan P; Geller J; Lieber MM; Elhilali M; Norman R; Patterson L; Perreault JP; Malek GH; Bruskewitz RC; Roy JB; Ko A; Jacobsen CA; Stoner E
    Urology; 1999 Apr; 53(4):690-5. PubMed ID: 10197842
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of male sexual function in patients with Lower Urinary Tract Symptoms (LUTS) associated with Benign Prostatic Hyperplasia (BPH) treated with a phytotherapeutic agent (Permixon), Tamsulosin or Finasteride.
    Zlotta AR; Teillac P; Raynaud JP; Schulman CC
    Eur Urol; 2005 Aug; 48(2):269-76. PubMed ID: 15939527
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Combination of Sabal and Urtica extract vs. finasteride in benign prostatic hyperplasia (Aiken stages I to II). Comparison of therapeutic effectiveness in a one year double-blind study].
    Sökeland J; Albrecht J
    Urologe A; 1997 Jul; 36(4):327-33. PubMed ID: 9340898
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Therapeutic effects of finasteride in benign prostatic hyperplasia: a randomized double-blind controlled trial.
    Yu HJ; Chiu TY; Lai MK
    J Formos Med Assoc; 1995; 94(1-2):37-41. PubMed ID: 7542109
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial.
    Kirby RS; Roehrborn C; Boyle P; Bartsch G; Jardin A; Cary MM; Sweeney M; Grossman EB;
    Urology; 2003 Jan; 61(1):119-26. PubMed ID: 12559281
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Treatment of benign prostatic hyperplasia with Proscar (finasteride). Results of a 10-year Scandinavian study].
    Tveter KJ; Beisland HO; Andersen JT; Wolf H; Ekman P; Johansson JE; Kontturi M; Lehtonen T
    Tidsskr Nor Laegeforen; 1996 Nov; 116(27):3226-30. PubMed ID: 9011975
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A risk-benefit assessment of treatment with finasteride in benign prostatic hyperplasia.
    Ekman P
    Drug Saf; 1998 Mar; 18(3):161-70. PubMed ID: 9530536
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sexual function in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia: results of a 6-month, randomized, double-blind, placebo-controlled study of tadalafil coadministered with finasteride.
    Glina S; Roehrborn CG; Esen A; Plekhanov A; Sorsaburu S; Henneges C; Büttner H; Viktrup L
    J Sex Med; 2015 Jan; 12(1):129-38. PubMed ID: 25353053
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treating benign prostatic hyperplasia with finasteride in Chinese men: one-year experience.
    Chueh SC; Yu HJ; Chiu TY; Huang CY; Lai MK
    J Formos Med Assoc; 1996 Aug; 95(8):650-2. PubMed ID: 8870441
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Incidence and severity of sexual adverse experiences in finasteride and placebo-treated men with benign prostatic hyperplasia.
    Wessells H; Roy J; Bannow J; Grayhack J; Matsumoto AM; Tenover L; Herlihy R; Fitch W; Labasky R; Auerbach S; Parra R; Rajfer J; Culbertson J; Lee M; Bach MA; Waldstreicher J;
    Urology; 2003 Mar; 61(3):579-84. PubMed ID: 12639651
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of baseline symptom severity on future risk of benign prostatic hyperplasia-related outcomes and long-term response to finasteride. The Pless Study Group.
    Kaplan S; Garvin D; Gilhooly P; Koppel M; Labasky R; Milsten R; Reddy P; Rosenberg S; Sussman D; White C; Lee M; Pappas F; Waldstreicher J
    Urology; 2000 Oct; 56(4):610-6. PubMed ID: 11018616
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 5alpha-reductase inhibitors: what role should they play?
    Kaplan SA
    Urology; 2001 Dec; 58(6 Suppl 1):65-70; discussion 70. PubMed ID: 11750255
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Five-alpha-reductase Inhibitors for prostate cancer prevention.
    Wilt TJ; MacDonald R; Hagerty K; Schellhammer P; Kramer BS
    Cochrane Database Syst Rev; 2008 Apr; 2008(2):CD007091. PubMed ID: 18425978
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A 5-year retrospective analysis of 5α-reductase inhibitors in men with benign prostatic hyperplasia: finasteride has comparable urinary symptom efficacy and prostate volume reduction, but less sexual side effects and breast complications than dutasteride.
    Kaplan SA; Chung DE; Lee RK; Scofield S; Te AE
    Int J Clin Pract; 2012 Nov; 66(11):1052-5. PubMed ID: 23067029
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term 6-year experience with finasteride in patients with benign prostatic hyperplasia.
    Lowe FC; McConnell JD; Hudson PB; Romas NA; Boake R; Lieber M; Elhilali M; Geller J; Imperto-McGinely J; Andriole GL; Bruskewitz RC; Walsh PC; Bartsch G; Nacey JN; Shah S; Pappas F; Ko A; Cook T; Stoner E; Waldstreicher J;
    Urology; 2003 Apr; 61(4):791-6. PubMed ID: 12670567
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combined sabal and urtica extract compared with finasteride in men with benign prostatic hyperplasia: analysis of prostate volume and therapeutic outcome.
    Sökeland J
    BJU Int; 2000 Sep; 86(4):439-42. PubMed ID: 10971268
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Placebo therapy of benign prostatic hyperplasia: a 25-month study. Canadian PROSPECT Study Group.
    Nickel JC
    Br J Urol; 1998 Mar; 81(3):383-7. PubMed ID: 9523656
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia. PLESS Study Group.
    Roehrborn CG; McConnell JD; Lieber M; Kaplan S; Geller J; Malek GH; Castellanos R; Coffield S; Saltzman B; Resnick M; Cook TJ; Waldstreicher J
    Urology; 1999 Mar; 53(3):473-80. PubMed ID: 10096369
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term treatment with finasteride improves clinical progression of benign prostatic hyperplasia in men with an enlarged versus a smaller prostate: data from the MTOPS trial.
    Kaplan SA; Lee JY; Meehan AG; Kusek JW;
    J Urol; 2011 Apr; 185(4):1369-73. PubMed ID: 21334655
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.